Leadership & Pay ·
Sarepta Therapeutics, Inc. announced the appointment of Michael Severino, M.D., as Chief Executive Officer, effective…
SRPTSarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. announced the appointment of Michael Severino, M.D., as Chief Executive Officer, effective July 28, 2026. Dr. Severino succeeds Douglas Ingram, who is retiring and will serve as a consultant to the company to ensure a smooth transition until December 31, 2026. Dr. Severino's compensation package includes an annual base salary of $1,180,000 and a sign-on equity grant with a value of approximately $35,000,000. Sarepta Therapeutics, Inc. is a biotechnology company that develops precision genetic medicine for rare diseases.